Trial 0S-16-15


Phase Ib Trial of Pembrolizumab (MK-3475) in Combination with Dinaciclib (MK-7965) in Subjects with Hematologic Malignancies (KEYNOTE-155)

Type: Treatment
Phase: Phase I
Status: Not Open (Closed)
Treatments: Biological Response Modifier
Randomized: No
USC Satellite Location: None
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Ann Mohrbacher, M.D.
Other Trial Staff:  Ibrahim Syed, Coordinator, Teresa Olea, R.N., Anastasia Martynova, D.M., Donna Fernando, Coordinator, Meena Ibrahim, D.M.

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.